LUND, Sweden, January 19, 2022 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the launch of a sponsored research collaboration to investigate biomarker data from Alligator’s OPTIMIZE-1 study with the University of Pennsylvania (UPENN) Pancreatic Cancer Research Center.
Gregory Beatty, MD, PhD, Assistant Professor of Medicine in the Division of Hematology/Oncology, UPENN, will act as faculty researcher for sponsored research agreements. Data analysis by Dr. Beatty and his team will be carried out at Beatty Laboratory at UPENN.
The focus of Dr. Beatty’s study will be to apply his analytical capabilities to data collected from patients receiving mFOLFIRINOX in combination with mitazalimab, Alligator’s CD40 agonist antibody. UPENN study is part of Alligator’s OPTIMIZE-1 clinical trial, an open-label, multicenter phase 1B/II evaluating the clinical efficacy of mitazalimab in combination with chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic cancer. Recruitment of OPTIMIZE-1 is planned for a maximum of 67 patients.
“The addition of the UPENN study, led by a researcher of the caliber of Dr. Beatty, to Alligator’s ongoing OPTIMIZE-1 lead is very exciting. The resulting data will provide additional and valuable information on opportunities for clinical development of mitazalimab in a patient. population with high unmet medical needs,” said Alligator CEO Søren Bregenholt. “We are also delighted to welcome Dr. Beatty as Scientific Advisor to Alligator.”
For more information, please contact:
Julie Silver, Investor Relations
Phone: +46 46-540 82 23
E-mail: [email protected]
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing immuno-oncology tumor-directed antibodies. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Additionally, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and new drug candidates based on the platform. bispecific RUBY™ with Orion Corporation. Our licensed programs include AC101, in Phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target for Biotheus Inc. Alligator Bioscience shares are listed on Nasdaq Stockholm (ATORX) and its headquarters are located at Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Alligator Bioscience